Trastuzumab, pertuzumab, and adotrastuzumab emtansine, are used for the treatment of ErbB2-positive breast cancer; adotrastuzumab emtansine is an antibody–drug conjugate that delivers a cytotoxic drug to cells overexpressing ErbB2. Here, ERBB2 is linked to breast carcinoma.